Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Crizotinib 2Bone Marrow Transplantation 23-Iodobenzylguanidine 2vorasidenib 1tucatinib 1tovorafenib 1tazemetostat 1taletrectinib 1olaparib 1nirogacestat 1glucarpidase 1enzalutamide 1denileukin diftitox 1copanlisib 1balstilimab 1atezolizumab 1adagrasib 1Proton Pump Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1LY3023414 1Hydrocortisone 1Carboxypeptidases 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Neoplasms × balstilimab × Clear all
NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Agenus Inc.

Available
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡